Mu and delta opioid receptor targeting reduces connexin 43-based heterocellular coupling during neuropathic pain

HIGHLIGHTS

• who: Nunzio Vicario et al. from the Section of Physiology, Department of Biomedical and Biotechnological Sciences, University of Catania, Oasi Research Institute-IRCCS, Troina, Italy have published the article: Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain, in the Journal: (JOURNAL)
• what: The authors aimed to investigate the therapeutic potential of LP2 . The aim of research in this field is to overcome typical side effects associated with selective opioid receptor agonism.
• how: The data showed that NLX in cotreatment with LP2 was not able to abolish . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.